Enfortumab Vedotin / Enfortumab vedotin-ejfv & Bladder cancer

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Enfortumab Vedotin/Enfortumab vedotin-ejfv is approved by both the FDA and EMA for the treatment of advanced Bladder cancer (1)

Enfortumab vedotin-ejfv / Enfortumab Vedotin has changed the standard of care treatment in Bladder cancer with a high response and disease-control rate, acceptable toxicity profile and improved overall survival for patient…

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
Yu et al. 2021c The Lancet Oncology 22: 872-882
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles et al. 2021 N Engl J Med 384: 1125-1135
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma
Mantia & Sonpavde 2022 Expert Review of Anticancer Therapy 22(5): 449-455
Review
Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma
McGregor & Sonpavde 2019 Expert Opin. Investig. Drugs 28: 821-826
Review
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Rosenberg et al. 2019a
Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
Moussa et al. 2021 Drug Des Devel Ther 15: 453-462
Review

11/5/2026